Tesamorelin / Ipamorelin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Tesamorelin / Ipamorelin is the clinic version of the growth hormone blend.
Evidence grade for Tesamorelin / Ipamorelin: Strong. The rule: at least two finished studies in people, and at least 1,000 people who took it. The sum on this page: 5 completed trials, 1,507 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 1,507
- Human studies
- 5
- Found nothing
- 1
Dose
Approved label amounts
1 and 2 mg
Amounts for the tesamorelin in the blend, in mg. 2 mg is the approved tesamorelin label; the ipamorelin moves with it in the label ratio.
9 effects reported, 6 unwanted, 3 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism, Brain, memory and mood, Hormones and growth hormone, Gut health
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is the clinic version of the growth hormone blend. One half is a real approved drug. It is sold as Egrifta and it takes belly fat off. The other half is a peptide with one human trial, and that trial missed. Nobody has ever tested the two together. A common vial is 5 mg of each.
What people take it for
- Losing belly fat, the deep kind around the organs.
- Better sleep.
- Holding muscle while losing fat.
- Sharper thinking, because the approved half has a small brain study behind it.
What studies in people showed
Split this page in two. The approved half is the real thing. In a trial of 412 people, 2 mg a day for 26 weeks cut deep belly fat by 15.2 percent. The dummy group gained 5.0 percent. A bigger look at 806 people found the same result, and skin fat did not change. A different trial gave 152 older adults 1 mg a day for 20 weeks. Thinking improved a bit, mostly on planning tasks, and IGF-1 went up 117 percent. The other half has one human trial. It went to 117 people after bowel surgery and did not beat a dummy shot. Now the blend. Nobody has tested it. And here is the trap. The only dose that ever produced the belly fat result is 2 mg a day. On a 5 and 5 vial, drawing 2 mg of the good half also gives you 2 mg of the other one. People who take that second peptide alone use about a tenth of that. Nobody has tested that dose in anyone. So most blend plans cut back to 1 mg instead. That fixes the second peptide and leaves you at half the dose the belly fat result came from. Either way, one half of the vial is off the dose its own evidence sits on.
What people report
Reports, not study results
The good
- Belly fat coming off over two to three months. The approved half does have trial data for this.
- Better sleep in the first few weeks, which people credit to the second peptide.
- Clothes fitting better even when the scale barely moves.
The bad
- Swollen hands, ankles and face, and stiff mornings. This shows up in the drug's own trial data, not just on forums.
- Aching joints and muscles.
- Blood sugar creeping up. Clinics check this for a reason, and the reason is trial data.
- Tingling or numb fingers.
- A sore red spot from a daily shot.
- You cannot drop one half. If your glucose climbs, you cut both or stop both, and you never learn which one caused it.
Where these come from: The swelling, joint pain and blood sugar effects come from the approved drug's own trial safety data. The sleep reports and the before and after stories come from clinic write ups and peptide forums, and there is no trial of the blend behind any of them. Two 2026 medical reviews of peptides sold straight to patients both say that expecting a result is a real part of what users report.
My bottom line
One half of this vial is a real drug with 806 patients behind it. The other half is riding on its name. If you want the drug, get the drug on its own, at the dose the trial used, with a doctor watching your blood sugar.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Tesamorelin / Ipamorelin has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing fat specifically1,370 people · 3 studies · 1 found nothing
- Memory and thinking152 people · 1 study
- Growth hormone and IGF-1152 people · 1 study
- Gut and digestion117 people · 1 study
What people using it report
Real people telling you what happened to them. Nobody checked it, and the people who post are not a fair sample, so it cannot prove anything works. It is still the best guide on this page to what people actually do with Tesamorelin / Ipamorelin, what they expect, and what goes wrong. The full account, including the negative reports, is below.
31 of the 36 indexed goals have no study of any kind behind Tesamorelin / Ipamorelin
No study in people, animals or cells on this page reports a result for these. That does not prove Tesamorelin / Ipamorelin does nothing for them. It does mean anything you have heard about Tesamorelin / Ipamorelin and one of these did not come from a study cited here.
Show full evidence
What is Tesamorelin / Ipamorelin?
Tesamorelin / Ipamorelin is the clinic version of the growth hormone blend. It pairs tesamorelin, a GHRH copy with FDA approval and results from 806 patients in large final-stage trials, with ipamorelin, whose one human trial missed its goal. No study has tested the two together. On the common 5 mg plus 5 mg vial, getting the 2 mg tesamorelin dose behind the approved result also gives you 2 mg of ipamorelin. That is roughly seven to ten times the dose ipamorelin is used at alone.
This is the blend that gets prescribed, rather than shipped in a plain box. It is also the one with the widest gap between the evidence for each part and the evidence for the blend.
Tesamorelin is a sturdier copy of GHRH, approved as Egrifta. In the main trial, 412 patients took 2 mg a day for 26 weeks. Their deep belly fat, the fat around the organs, fell 15.2 percent. On a dummy shot it rose 5.0 percent. A pooled look at 806 patients from both large final-stage trials found deep belly fat fell 24 square centimetres on the drug, against a 2 square centimetre rise on the dummy. Fat just under the skin did not change. That is a real drug with a real result at a set dose.
Ipamorelin has one published human trial. In 117 people who had bowel surgery, it was well tolerated. It did not clearly shorten the time to a first meal they could keep down: 25.3 hours, against 32.6 hours on a dummy drip.
The pair has never been studied. Not in a trial, not in a set of case reports, not in animals. What is sold is a pharmacy-made or gray-market mix, in one of two common setups. One is 5 mg tesamorelin with 5 mg ipamorelin, half of each by weight. The other is 10 mg tesamorelin with 3 mg ipamorelin, about 77 percent tesamorelin and 23 percent ipamorelin. By number of molecules, an equal-weight vial is nothing like equal. Tesamorelin weighs 5,135.9 Da and ipamorelin weighs 711.85 Da. So a 1:1 blend by weight gives about 7.2 ipamorelin molecules for every tesamorelin molecule.
Here is the problem the fixed split creates, and it is sharper on this blend than on any other page in this group. The only tesamorelin dose that ever produced the belly fat result is 2 mg a day. Mix a 5 plus 5 vial with 2 mL and you have 2.5 mg per mL of each. So 2 mg of tesamorelin is a 0.8 mL draw, or 80 units on an insulin syringe, and it brings 2 mg of ipamorelin with it. People who take ipamorelin on its own usually use 200 to 300 micrograms. Nobody has published what 2 mg of ipamorelin a day does to a person. On the 10 plus 3 vial, the same 2 mg of tesamorelin comes with 600 micrograms of ipamorelin. That is still two to three times the usual single-peptide dose.
Most blend routines dodge this by taking 1 mg of tesamorelin instead of 2 mg. That drops the ipamorelin to 500 to 1,000 micrograms. It also drops the tesamorelin to half the approved dose. The 1 mg dose has its own human data, for a different goal. In a 20-week trial of 152 adults aged 55 to 87, it had a helpful effect on thinking, mainly planning and mental flexibility. IGF-1 rose 117 percent while staying in the normal range. That trial was not testing belly fat, so it did not show the belly fat result. Whichever way the blend is dosed, one of the two peptides is off the dose its evidence rests on.
How does Tesamorelin / Ipamorelin work?
Tesamorelin presses the GHRH switch in the pituitary. That makes the body's own growth hormone bursts bigger, while the brain's feedback checks stay in place. That is what let it cut deep belly fat without the effects of giving growth hormone directly. Ipamorelin presses the ghrelin switch, GHS-R1a, on the same cell. That is a separate route that also releases growth hormone and eases off somatostatin, the body's brake on growth hormone. The idea is that two different switches give a bigger burst than either alone. That holds for GHRH plus GHRP-type peptides in one-time human tests. It has not been tested for this pair.
What have studies in people found about Tesamorelin / Ipamorelin?
One half of this blend has some of the strongest human evidence in this database. The other half has one trial that found no clear benefit. Neither fact is evidence about the blend, which has never been given to a person in a published study.
- Tesamorelin 2 mg a day, 412 patients, 26 weeks: deep belly fat down 15.2 percent, against a 5.0 percent rise on a dummy shot.
- Tesamorelin, 806 patients pooled from two large final-stage trials: deep belly fat down 24 square centimetres, against a 2 square centimetre rise on a dummy shot. Fat under the skin did not change.
- Tesamorelin 1 mg a day, 152 older adults, 20 weeks: a helpful effect on thinking, mainly planning and mental flexibility, and IGF-1 up 117 percent while staying in the normal range.
- Ipamorelin, 117 people after bowel surgery: well tolerated, but it did not clearly shorten the time to a first meal they could keep down, compared with a dummy drip.
- GHRH plus GHRP-6 in 20 patients roughly doubled the one-time growth hormone peak, compared with GHRP-6 alone.
What this does not tell you: Every tesamorelin number above comes from people with HIV-related fat buildup, or from older adults in a thinking trial. None comes from healthy adults taking it to change their body shape. None was produced with ipamorelin on board. The ipamorelin trial gave it through a vein, for a short time. Nothing here sets a dose for the pair or a split for the pair, or shows the pair stays stable in one vial. And nothing deals with the key practical fact: on a 1:1 vial, you cannot reach the proven tesamorelin dose without also taking an untested ipamorelin dose.
What do people who took Tesamorelin / Ipamorelin report?
This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.
- Visible loss of belly fat over two to three months. This is what people buy the blend for, and tesamorelin alone does have trial data behind it.
- Better sleep in the first weeks, which users credit to the ipamorelin.
- Swelling and puffiness in the hands, ankles and face, and stiffness in the morning. Water retention is a known tesamorelin effect and is on its label.
- Aching joints and muscles.
- Rising fasting blood sugar or HbA1c (a three-month blood sugar average) on follow-up blood tests. This is a known concern when you push the growth hormone system, and it is why clinics check it.
- Tingling or numbness in the fingers.
- Redness where the shot goes in, which is common with a daily shot under the skin.
Sources: Fluid retention, arthralgia and glucose effects appear in the tesamorelin Phase 3 safety data and its FDA labelling, which is trial-derived. The sleep reports, the timelines and the abdominal fat impressions are from clinic write-ups and peptide user forums and are not from any trial of the blend. The 2026 Sports Medicine and Frontiers in Endocrinology reviews both say belief alone is a real contributor to what users report on unapproved peptides.
The state of the research
This page exists because the blend borrows trust that belongs to only one of its halves. Tesamorelin's approval, its 806-patient data and its New England Journal of Medicine paper are real. They are often shown as if they apply to a vial that also holds something else, at about seven times as many molecules. They do not. Keeping what is proven for tesamorelin apart from what is claimed for tesamorelin plus ipamorelin is the whole job of this page.
The second thing to say plainly: the tesamorelin result was measured in one group of people with one problem. Deep belly fat from HIV-related fat buildup is its own condition, and the FDA label reflects that. Nobody has tested to the same standard whether a healthy 45-year-old loses deep belly fat on tesamorelin, with or without a second peptide.
And the same fixed-split trap applies here as on every blend page. Tesamorelin's known effects include water retention, joint pain and a rise in blood sugar. If any of those show up, a blend only lets you lower both peptides or stop entirely. You cannot keep the tesamorelin and drop the ipamorelin, or the other way round. And you can never find out which one was to blame.
The evidence, in charts
Fig. 1a · how many people
1,507people, across 5 studies in people cited here
| Study | People | Share |
|---|---|---|
| Journal of Clinical Endocrinology and Metabolism 2010 | 806 | 53% |
| New England Journal of Medicine 2007 | 412 | 27% |
| Archives of Neurology 2012 | 152 | 10% |
| International Journal of Colorectal Disease 2014 | 117 | 8% |
| European Journal of Endocrinology 2002 | 20 | 1% |
One study holds 53% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
5 of 6 sources here are studies in people. The rest is not.
- Study in people · done in people583%
- Review of studies · sums up other studies117%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 6 different years, 2002 to 2026, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Not approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, by prescription in 0, not approved in 3. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Blend
- Molecule weight
- Mixture; tesamorelin 5,135.9 Da, ipamorelin 711.85 Da
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not one number. Both components clear within hours, but not at the same rate, and neither has been measured in the presence of the other.
No amino acid sequence is on file for Tesamorelin / Ipamorelin, which is expected: a blend is not built from amino acids.
Fig. 6 · what is in the vial
We cannot show how much of each is in this blend
Sellers do not agree on a vial size for Tesamorelin with ipamorelin, so nobody outside can know how much of each ingredient is in it. Splitting the bar evenly would make up the very number this page is here to question.
- TesamorelinStrong. At least two finished studies in people, and at least 1,000 people who took it. 8 completed trials, 1,729 people given it.amount not stated
- IpamorelinModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 157 people given it.amount not stated
Ingredient list from the product labels we have. Amounts are what the label says is in the vial, never a dose.
The studies we cite
- Study in people2007Metabolic effects of a growth hormone-releasing factor in patients with HIV
Tesamorelin on its own shrank the deep fat around the organs in people with HIV. Four hundred and twelve patients took a 2 mg shot daily for six months, or a dummy shot. That fat fell by about 15 percent on the drug while it rose 5 percent on the dummy, and blood fats improved too. No ipamorelin was given. The dose here is 2 mg a day, which is the dose the approval rests on.
412 patients with HIV and abdominal fat accumulation. Twenty-six weeks of tesamorelin at 2 mg daily reduced visceral adipose tissue by 15.2 percent against a 5.0 percent increase on placebo, with lower triglycerides. This is tesamorelin alone at 2 mg. No ipamorelin was given, and 2 mg daily is the dose the approval rests on.
- Study in people2010Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
The largest pile of evidence on either half of this blend, and it is for tesamorelin alone. Eight hundred and six patients were pooled from the two main trials. The deep fat around the organs fell on the drug and rose slightly on the dummy, a difference of about 15 percent. Fat just under the skin did not change, so this is a targeted effect rather than general weight loss. Nobody in these trials was given ipamorelin.
806 patients pooled across both Phase 3 trials. Visceral fat fell 24 square centimetres at week 26 against a 2 square centimetre rise on placebo, a treatment effect of minus 15.4 percent, with no change in subcutaneous fat. The largest dataset on either component of this blend, and it is tesamorelin monotherapy.
- Study in people2012Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
A low dose of tesamorelin nudged thinking in the right direction in older adults. A hundred and fifty two people aged 55 to 87 took it or a dummy shot for five months, and sixty six of them already had mild memory trouble. The gain showed up mainly in planning and mental flexibility. IGF-1 more than doubled while staying inside the normal range. The dose was 1 mg, half the dose used for belly fat, and this trial did not measure fat at all.
152 adults aged 55 to 87, of whom 66 had mild cognitive impairment. Twenty weeks of tesamorelin at 1 mg daily had a favourable effect on cognition, P equal to 0.03, concentrated in executive function, and raised IGF-1 by 117 percent within the physiological range. Note the dose: 1 mg, which is half the dose that produced the visceral fat result, and this trial did not measure visceral fat.
- Study in people2014Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
Ipamorelin has been tested in people once, and it failed. A hundred and seventeen patients who had just had bowel surgery were given it into a vein or a dummy. On average they managed a meal sooner, 25.3 hours against 32.6, but the gap was too small to separate from chance. The drug was well tolerated. This is the entire published human record for the ipamorelin half of the blend, and it is about recovery from surgery.
Phase 2 randomised controlled trial in 117 surgical patients. Intravenous ipamorelin was well tolerated but did not significantly shorten time to a first tolerated meal against placebo, 25.3 hours versus 32.6 hours, P equal to 0.15. This is the entire published human record for the ipamorelin half of the blend, and it is a null result on a different question.
- Study in people2002Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test
The idea behind pairing these two kinds of peptide has been shown in people once, as a hospital test. Twenty patients were given a ghrelin type drug alone, then the same drug with a growth hormone releasing hormone. The peak growth hormone roughly doubled when the two were combined. That is the principle vendors point at. The drugs were not tesamorelin and ipamorelin, the dose went into a vein, and it was given once as a test of the pituitary rather than as treatment.
Twenty patients. Mean peak growth hormone was 25.7 micrograms per litre on GHRP-6 alone and 54.7 micrograms per litre when GHRH was added, in the growth hormone sufficient group. The class principle behind pairing a GHRH analogue with a ghrelin mimetic, demonstrated as a one-off intravenous diagnostic test with GHRH and GHRP-6, not with tesamorelin and ipamorelin.
- Review of studies2026Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
A review of peptides sold straight to patients for injuries and sport, including tesamorelin, ipamorelin, CJC-1295 and sermorelin. Many unapproved peptides look good in animals, but good human safety data is scarce. The authors say the dummy-pill effect and social media hype both drive the benefits people report.
Narrative review covering tesamorelin, ipamorelin, CJC-1295, sermorelin and others sold direct to patients. Many unapproved peptides show favourable outcomes in animal models while rigorous human safety data are scarce, and the authors treat the placebo effect and social media amplification as active mediators of reported peptide benefit.
Where to buy Tesamorelin / Ipamorelin
76 sellers list Tesamorelin / Ipamorelin in our latest read. They are ranked by trust score, then by archive rating, then by certificate tier, then by the lowest price per milligram. Archive evidence is counted before source-backed. Each path is out of 4, and the two are not added. A higher price does not raise the score. The letter is the certificate chip. 0 of them have a published certificate that names Tesamorelin / Ipamorelin.
Some seller links may pay this site when you buy through them. A payment never changes a seller's tier or rank, and no seller has a say in any page.
| Seller | Trust score | Vial sizes | From, per mg | Certificate for Tesamorelin / Ipamorelin | Seller link |
|---|---|---|---|---|---|
| Panda Peptides | 85 StrongSource-backed 4 of 4. Archive evidence 3 of 4.A | 13 mg | $5.00 | None found for Tesamorelin / Ipamorelin | View |
| S1 Research | 85 StrongSource-backed 4 of 4. Archive evidence 2 of 4.A | 13 mg | $5.00 | None found for Tesamorelin / Ipamorelin | View |
| MyPurePeptide | 80 StrongSource-backed 3 of 4. Archive evidence 2 of 4.A | 12 mg, 17 mg | $2.92 | None found for Tesamorelin / Ipamorelin | View |
| Peptide Power US | 77 StrongSource-backed 4 of 4. Archive evidence 2 of 4.A | 30 mg | $7.83 | None found for Tesamorelin / Ipamorelin | View |
| EZ Peptides | 75 StrongSource-backed 4 of 4. Archive evidence 3 of 4.A | 10 mg | $8.80 | None found for Tesamorelin / Ipamorelin | View |
| BioGenix Peptides | 75 StrongSource-backed 4 of 4. Archive evidence 2 of 4.A | 10 mg | $8.90 | None found for Tesamorelin / Ipamorelin | View |
| Core Peptides | 75 StrongSource-backed 4 of 4. Archive evidence 2 of 4.A | 8 mg | $11.3 | None found for Tesamorelin / Ipamorelin | View |
| LiveWell Peptides | 73 StrongSource-backed 4 of 4. Archive evidence 2 of 4.A | 5 mg, 10 mg | $20.0 | None found for Tesamorelin / Ipamorelin | View |
| Simons RX | 70 StrongSource-backed 4 of 4. Archive evidence 2 of 4.A | 15 mg | $8.60 | None found for Tesamorelin / Ipamorelin | View |
| Qureshi Labs | 70 StrongSource-backed 3 of 4. Archive evidence 2 of 4.A | 10 mg | $10.00 | None found for Tesamorelin / Ipamorelin | View |
| NuLife Peptides | 67 FairSource-backed 3 of 4. Archive evidence 2 of 4.B | 12 mg, 14 mg, 15 mg, 20 mg | $6.00 | None found for Tesamorelin / Ipamorelin | View |
| Peptide Plugs | 65 FairSource-backed 4 of 4. Archive evidence 2 of 4.A | 16 mg | $5.00 | None found for Tesamorelin / Ipamorelin | View |
| PeptidePlugs | 65 FairSource-backed 4 of 4. Archive evidence 2 of 4.A | 16 mg | $5.00 | None found for Tesamorelin / Ipamorelin | View |
| Purified Peptide | 63 FairSource-backed 4 of 4. Archive evidence 1 of 4.B | 13 mg | $5.77 | None found for Tesamorelin / Ipamorelin | View |
| Peak Peptides | 55 FairSource-backed 2 of 4. Archive evidence 1 of 4.C | 18 mg | $7.22 | None found for Tesamorelin / Ipamorelin | View |
| BioPure Peptides | 51 FairSource-backed 4 of 4. Archive evidence 1 of 4.B | 5 mg | $19.0 | None found for Tesamorelin / Ipamorelin | View |
| Protide Health | 50 FairSource-backed 2 of 4. Archive evidence 1 of 4.C | 3 mg, 5 mg, 12 mg | $10.0 | None found for Tesamorelin / Ipamorelin | View |
| Biotech Peptides | 49 WeakSource-backed 3 of 4. Archive evidence 3 of 4.A | 8 mg | $11.3 | None found for Tesamorelin / Ipamorelin | View |
| Zenergy USA | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 12 mg, 15 mg | $2.73 | None found for Tesamorelin / Ipamorelin | View |
| Forge Performance Co. | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 16 mg | $5.00 | None found for Tesamorelin / Ipamorelin | View |
| Liberty Peptides | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 3 mg, 12 mg | $6.33 | None found for Tesamorelin / Ipamorelin | View |
| Apex Amino | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 15 mg | $6.67 | None found for Tesamorelin / Ipamorelin | View |
| Molecular Edge Peptides | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 12 mg, 20 mg | $8.75 | None found for Tesamorelin / Ipamorelin | View |
| Lifetime Peptides | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 10 mg | $9.90 | None found for Tesamorelin / Ipamorelin | View |
| Novara Peptides | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 13 mg | $9.92 | None found for Tesamorelin / Ipamorelin | View |
| Core Peptides Official | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 8 mg | $10.0 | None found for Tesamorelin / Ipamorelin | View |
| Peptide Labs | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 10 mg, 20 mg | $10.3 | None found for Tesamorelin / Ipamorelin | View |
| Onyx Research | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 10 mg | $10.3 | None found for Tesamorelin / Ipamorelin | View |
| San Diego Peptides | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 10 mg | $11.0 | None found for Tesamorelin / Ipamorelin | View |
| Pristine Aminos | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 5 mg | $14.0 | None found for Tesamorelin / Ipamorelin | View |
| Evolve Peptides | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 5 mg, 10 mg | $15.0 | None found for Tesamorelin / Ipamorelin | View |
| Lost Coast Aminos | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 3 mg | $17.3 | None found for Tesamorelin / Ipamorelin | View |
| Gila Peptides | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 5 mg, 10 mg | $17.5 | None found for Tesamorelin / Ipamorelin | View |
| Cenexa Labs | 49 WeakSource-backed 2 of 4. Archive evidence 2 of 4.B | 15 mg | $7.67 | None found for Tesamorelin / Ipamorelin | View |
| Genoscience | 49 WeakSource-backed 2 of 4. Archive evidence 2 of 4.B | 7 mg | $8.57 | None found for Tesamorelin / Ipamorelin | View |
| Peptide Shop A | 49 WeakSource-backed 2 of 4. Archive evidence 2 of 4.B | 8 mg | $11.3 | None found for Tesamorelin / Ipamorelin | View |
| Alpha Peps | 49 WeakSource-backed 2 of 4. Archive evidence 2 of 4.B | 5 mg | $14.0 | None found for Tesamorelin / Ipamorelin | View |
| Peplogix | 49 WeakSource-backed 3 of 4. Archive evidence 1 of 4.B | 10 mg, 20 mg | $8.75 | None found for Tesamorelin / Ipamorelin | View |
| Pure Tested Peptides | 49 WeakSource-backed 3 of 4. Archive evidence 1 of 4.B | 3 mg | $40.0 | None found for Tesamorelin / Ipamorelin | View |
| Sigma Compounds | 49 WeakSource-backed 3 of 4. Archive evidence 1 of 4.B | 3 mg | $42.3 | None found for Tesamorelin / Ipamorelin | View |
| Pure Peptide Factory | 48 WeakSource-backed 1 of 4. Archive evidence 1 of 4.C | 15 mg | $4.00 | None found for Tesamorelin / Ipamorelin | View |
| Solution Peptides | 48 WeakSource-backed 1 of 4. Archive evidence 0 of 4.C | 15 mg | $6.60 | None found for Tesamorelin / Ipamorelin | View |
| Raw Amino | 46 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 8 mg | $12.6 | None found for Tesamorelin / Ipamorelin | View |
| Atomik Labz | 43 WeakSource-backed 1 of 4. Archive evidence 0 of 4.C | 12 mg | $8.25 | None found for Tesamorelin / Ipamorelin | View |
| Peptides.com | 42 WeakSource-backed 2 of 4. Archive evidence 2 of 4.B | 13 mg | $6.92 | None found for Tesamorelin / Ipamorelin | View |
| Warrior Makers | 42 WeakSource-backed 2 of 4. Archive evidence 2 of 4.B | 10 mg, 13 mg | $12.9 | None found for Tesamorelin / Ipamorelin | View |
| PeptiMed | 41 WeakSource-backed 1 of 4. Archive evidence 1 of 4.C | 2 mg | $35.0 | None found for Tesamorelin / Ipamorelin | View |
| Oath Research | 40 WeakSource-backed 1 of 4. Archive evidence 1 of 4.C | 8 mg, 12 mg | $12.1 | None found for Tesamorelin / Ipamorelin | View |
| Umbrella Labs | 39 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 10 mg, 15 mg, 25 mg | $6.67 | None found for Tesamorelin / Ipamorelin | View |
| Peptides World | 39 WeakSource-backed 4 of 4. Archive evidence 1 of 4.B | 2 mg, 3 mg, 8 mg | $11.2 | None found for Tesamorelin / Ipamorelin | View |
| Limitless Biotech ST | 36 WeakSource-backed 1 of 4. Archive evidence 1 of 4.C | 8 mg | $11.3 | None found for Tesamorelin / Ipamorelin | View |
| Lejian Biotech Peptide | 35 WeakSource-backed 1 of 4. Archive evidence 1 of 4.C | 8 mg | $10.6 | None found for Tesamorelin / Ipamorelin | View |
| Amino Sequence | 33 WeakSource-backed 1 of 4. Archive evidence 1 of 4.C | 20 mg | $4.00 | None found for Tesamorelin / Ipamorelin | View |
| Paramount Peptides | 33 WeakSource-backed 1 of 4. Archive evidence 0 of 4.C | 12 mg, 15 mg | $5.38 | None found for Tesamorelin / Ipamorelin | View |
| Southern Aminos | 29 InsufficientSource-backed 4 of 4. Archive evidence 1 of 4.Letter withheld | 10 mg, 20 mg | $5.00 | None found for Tesamorelin / Ipamorelin | View |
| Soma Peptides | 29 InsufficientSource-backed 4 of 4. Archive evidence 1 of 4.Letter withheld | 8 mg, 16 mg | $10.6 | None found for Tesamorelin / Ipamorelin | View |
| LabRat Peptides | 28 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C | 12 mg | $4.58 | None found for Tesamorelin / Ipamorelin | View |
| Peptides AZ | 28 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C | 15 mg | $18.0 | None found for Tesamorelin / Ipamorelin | View |
| Modern Aminos | 28 InsufficientSource-backed 1 of 4. Archive evidence 0 of 4.C | 10 mg | $8.40 | None found for Tesamorelin / Ipamorelin | View |
| Welli Labs | 27 InsufficientSource-backed 1 of 4. Archive evidence 0 of 4.Letter withheld | 16 mg | $5.62 | None found for Tesamorelin / Ipamorelin | View |
| True Research Labs | 25 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C | 15 mg | $6.60 | None found for Tesamorelin / Ipamorelin | View |
| MJA Peptides | 25 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C | 8 mg | $10.6 | None found for Tesamorelin / Ipamorelin | View |
| ZL Peptides | 25 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C | 8 mg | $10.6 | None found for Tesamorelin / Ipamorelin | View |
| Peptide Science LLC | 25 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C | 8 mg | $13.8 | None found for Tesamorelin / Ipamorelin | View |
| USA Peptide Sciences | 25 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C | 8 mg | $13.8 | None found for Tesamorelin / Ipamorelin | View |
| Neuro Labs | 25 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C | 3 mg | $51.3 | None found for Tesamorelin / Ipamorelin | View |
| Pura Peptides | 25 InsufficientSource-backed 1 of 4. Archive evidence 0 of 4.C | 10 mg | $11.0 | None found for Tesamorelin / Ipamorelin | View |
| Cernum Biosciences | 18 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C | 4 mg | $23.2 | None found for Tesamorelin / Ipamorelin | View |
| Nexa Peptide Store | 18 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C | 13 mg | $25.2 | None found for Tesamorelin / Ipamorelin | View |
| AMC Essentials | 16 InsufficientSource-backed 1 of 4. Archive evidence 0 of 4.Letter withheld | 20 mg | $4.75 | None found for Tesamorelin / Ipamorelin | View |
| Tydes | 15 InsufficientSource-backed 1 of 4. Archive evidence 0 of 4.Letter withheld | 2 mg | $42.5 | None found for Tesamorelin / Ipamorelin | View |
| Glacier Aminos | 12 InsufficientSource-backed 4 of 4. Archive evidence 2 of 4.Letter withheld | 13 mg | $8.08 | None found for Tesamorelin / Ipamorelin | View |
| Wellness Peptides | 10 InsufficientSource-backed 3 of 4. Archive evidence 0 of 4.Letter withheld | 10 mg | $7.50 | None found for Tesamorelin / Ipamorelin | View |
| Skye Peptides | 0 InsufficientSource-backed 3 of 4. Archive evidence 1 of 4.Letter withheld | 2 mg, 5 mg | $15.8 | None found for Tesamorelin / Ipamorelin | View |
| Aminos Research | 0 InsufficientSource-backed 1 of 4. Archive evidence 0 of 4.Letter withheld | 10 mg | $7.50 | None found for Tesamorelin / Ipamorelin | View |
| Apex Peptides | 0 InsufficientSource-backed 1 of 4. Archive evidence 0 of 4.Letter withheld | 2.5 mg, 5 mg, 10 mg | $10.0 | None found for Tesamorelin / Ipamorelin | View |
- LC Lab-confirmed: the issuing laboratory echoed this certificate back
- A Current certificate, independent laboratory named, laboratory not yet checked
- B Certificate published, but no laboratory link, older than a year, or the laboratory did not recognise the published lookup
- C No certificate could be read
Every listing and vial size for Tesamorelin / Ipamorelin · How the trust score is counted
Sellers named on the price pages are ranked by certificate tier, then price, and any affiliate income is disclosed there. Naming a seller is not a recommendation to buy or use anything.
Common questions
Has Tesamorelin / Ipamorelin been tested in people?
Yes. 1,507 people given it across 5 completed trials cited here, 1 of which found nothing. Tesamorelin / Ipamorelin is the clinic version of the growth hormone blend.
What is the Tesamorelin / Ipamorelin dosage?
Approved label amounts. 1 and 2 mg Amounts for the tesamorelin in the blend, in mg. 2 mg is the approved tesamorelin label; the ipamorelin moves with it in the label ratio.
Is Tesamorelin / Ipamorelin FDA-approved?
Not approved as a blend. Tesamorelin alone is FDA-approved as Egrifta, for the shifted body fat some people with HIV get. Ipamorelin is not approved, and no combination product exists.
Is this blend the same as the approved drug Egrifta?
No. Egrifta is tesamorelin alone, at 2 mg a day, approved for HIV-related fat buildup. The blend adds a second, unapproved peptide in a fixed split. It has never been reviewed or studied as a product. The approval belongs to one ingredient, not to the vial.
How much ipamorelin am I getting if I dose the tesamorelin properly?
On a 5 mg plus 5 mg vial, more than anyone has studied. Mixed with 2 mL, you have 2.5 mg per mL of each. So the 2 mg of tesamorelin behind the approved belly fat result is an 80 unit draw, and it carries 2 mg of ipamorelin. Ipamorelin on its own is usually taken at 200 to 300 micrograms. On a 10 mg plus 3 mg vial, the same tesamorelin dose brings 600 micrograms of ipamorelin. That is still two to three times the usual.
Does the ipamorelin add anything?
Nobody has measured it in this pair. The general idea is supported: in a 20-patient hospital test, adding a ghrelin copy to GHRH roughly doubled the one-time growth hormone peak. Whether that turns into any extra fat loss, muscle or recovery on top of tesamorelin has not been tested by anyone.
Why do most blend protocols use 1 mg of tesamorelin instead of 2 mg?
Because 2 mg on a 1:1 vial drags a huge ipamorelin dose along with it. The trade-off is that 1 mg is half the dose the belly fat result came from. The 1 mg dose does have human data, from a thinking trial in 152 older adults. But that trial did not measure body fat.
Do I need bloodwork on this?
Fasting blood sugar and HbA1c (your three-month blood sugar average) are the ones that matter. Pushing the growth hormone system can raise both, and that worry comes from tesamorelin's own trial data, not from forums. IGF-1 tells you the system is being pushed. That is not the same as telling you anything is getting better.
Can I stop just the ipamorelin if I do not like something?
Not from one vial. That is the cost of any blend, and it is the part nobody selling it mentions. Whatever side effect shows up, you can only lower both or stop both. And you will never know which peptide caused it.